Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2007

View Archived Issues

Dose-dependent occupancy of brain CB-1 receptors seen with taranabant

Positive results for XenoPort's phase I safety trials of XP-19986

Positive results for Vernalis' phase I V-24343 program for weight loss

Targeting Fyn protein kinase could lead to novel antipsychotic drugs

Targeting IL-23 shows benefit in models of multiple sclerosis in vivo

Allon provides clinical update

XOMA-052 enters clinic for type 2 diabetes

Genmab reveals HuMax-Inflam target

Patient dosing with OTS-102 begins at OncoTherapy Science

Adlea enters phase II clinical evaluation for TKA

FDA continues review of Entereg; clinical hold continues

Targanta to evaluate simplified oritavancin dosing regimens in phase II

AlphaRx to evaluate iNOS inhibitor for inflammation in preclinical studies

Patient enrollment begins in lubiprostone phase III clinical study for OBD

Spectrum's NDA for ISO-Vorin nears FDA decision

Isis and Ortho-McNeil establish antisense drug development collaboration

Positive phase I results encourage Pharmacopeia to expand dose of PS-433540

Ziopharm begins dosing patients in phase I trials of oral ZIO-101 and ZIO-301

Repros' IND for Proellex approved; phase II trial being planned

Research agreement for stem cell delivery to damaged organs signed

Targeting PPARalpha shows benefit in a model of circadian rhythm sleep disorder

Health Canada accepts new drug submission of ceftobiprole for cSSSI

Eli Lilly's Evista approved by FDA for new indication

Recent Taisho and Daiichi patents impart new therapeutic agents for autoimmune diseases

Recent patents disclose novel antiinfective agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...